Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
2000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-03-28
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection/risk assessment and diagnostic purposes. However, large macromolecules are not likely suspended nor readily detected in the breath. In particular, genomic DNA in the breath condensate (EBC) is very sparse, and where present, generally highly fragmented, not readily amenable to sequencing based assessments of DNA somatic mutation burden or distribution. Because gDNA (and protein) is challenging to obtain non-invasively from EBC, the study team considered alternative surrogate lower airway specimens. Cough capture is rarely done, and the investigator team is in the process of optimizing its collection. Importantly, the team will be evaluating how much of coughed material is from saliva contamination. Additionally, analyzing material that is target captured by capturing deep lung extracellular vesicles (EVs) using immobilized CCSP/SFTPC antibodies targeting EVs from distal bronchiole Club and alveolar type 2 cells could circumvent the mouth contamination problem, leaving a non-invasive portal to the deep lung suitable for large molecules, and in turn suitable for myriad epidemiologic and clinical applications.
The investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL/bronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg/Maslov labs. Finally, the investigator team will (Aim 3) test all airway specimens (cough, mouthwash and BAL) for lung surrogacy of cough, using proteins known to be specific for lung, as opposed to oral cavity/saliva, in the Sidoli/proteomics core.
The investigator team envisions that the translational impact of non-invasively obtained DNA or protein markers could allow for more rapid acute clinical diagnoses, and facilitate precision prevention and/or early detection of many acute and chronic respiratory disorders, including lung cancer, asthma and COPD, acute and chronic infectious diseases, and indeed systemic disorders of inflammation and metabolism.
The investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL/bronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg/Maslov labs. Finally, the investigator team will (Aim 3) test all airway specimens (cough, mouthwash and BAL) for lung surrogacy of cough, using proteins known to be specific for lung, as opposed to oral cavity/saliva, in the Sidoli/proteomics core.
The investigator team envisions that the translational impact of non-invasively obtained DNA or protein markers could allow for more rapid acute clinical diagnoses, and facilitate precision prevention and/or early detection of many acute and chronic respiratory disorders, including lung cancer, asthma and COPD, acute and chronic infectious diseases, and indeed systemic disorders of inflammation and metabolism.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients
NCT03685669
Lung Nodule
UNKNOWN
Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC
NCT07186855
Lung Cancer (NSCLC)
COMPLETED
Breath Test for Early Detection of Lung Cancer
NCT00639067
Lung Neoplasms
COMPLETED
Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease
NCT00733252
Lung Cancer
Malignant Mesothelioma
Metastatic Cancer
+2 more
WITHDRAWN
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
NCT04968548
Lung Cancer
ACTIVE_NOT_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis: Cough can serve as a valid non-invasive surrogate for the lung for large molecules such as DNA and proteins, potentially for a variety of clinical and public health purposes.
Proposal in Brief: For development of an epidemiological and clinically-applicable platform for large molecules captured uniquely from deep lung, the investigator team will pursue a new approach that includes cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL/bronchial brushings, and to the potential contaminating mouthrinse, all from the same individuals. The study team initially proposes to examine these crude cough specimens, and then EV partitioned airway samples, for somatic mutations by SMM bulk sequencing for somatic mutations, state-of-art techniques developed in the Vijg/Maslov labs and for proteins known to be specific for lung, as opposed to oral cavity/saliva, in the Sidoli/proteomics core.
Specific Aims:
1. Cough will be captured by aerochamber or equivalent/optimized device in 5 healthy volunteers, and in 5 current smokers, in parallel with mouthrinse and with BAL. Lung-specific EVs from these same samples via deep lung capture (Loudig lab) will be performed in parallel.
2. Cough will undergo DNA mutation analyses using single molecule mutation sequencing (SMM-seq).
3. Cough, mouthwash and BAL will undergo proteomic analysis using LC-MS in our Core facility.
Aims 1 and 2 will be studied in a cross-sectional manner, enrolling a convenience sample of PLWHA smokers attending the Montefiore Medical Center (MMC) Infectious Diseases (ID) Clinic. During Aim 1, group EBC DNA methylation and microRNA and metabolomics patterns will be determined by high resolution tagged bisulfite genomic sequencing of three tumor suppressor genes (DAPK, RASSF1A, PAX5B), according to smoking status (current, former, never), and lifelong dose (pack-years) in a sample of HIV-infected smokers. Aim 2 will pilot the comparison of EBC DNA methylation and microRNA and metabolomics patterns from HIV infected individuals to that from uninfected individuals, collected in other projects funded by other mechanisms. Aim 3 will employ a prospective design, collecting two specimens over time from a subset of the overall study sample to examine the stability of EBC DNA and microRNA and metabolomics patterns methylation patterns over time in HIV-infected smokers.
Approach:
Human Lung Studies protocol practices, in general: Ongoing subject enrollment is part of a longstanding IRB-approved Einstein-Montefiore clinical case-control protocol (2007-407). Individuals from pulmonary practices eligible to enroll are: Age \> 21 years old, any smoking status, myriad comorbid status except contraindications to BAL, planned for clinically-indicated lung collection procedure (bronchoscopy) as part of routine care. This amounts to \>100-150 bronchoscopy and related former smoker donors recruits per year. Over 150-200 such pre-existing bronchoscopic sample sets, and attendant non-invasive EBC, along with MW, buccal brush, others\] are banked and potentially available for the current study. All data/specimens are collected pre-diagnosis and pre-procedure; each subject provides EBC (and other non-invasives such as Cough) samples pre- bronchoscopy. As such, this active protocol minimizes (i) recall bias; and (ii) contamination of non-invasive specimens from the disruptions and spillage of the lung tissue inherent to these lung procedures. Each subject will be followed for 3 months in the medical record to gather updated diagnostics/testing, and minimize case-control misclassification. Extensive demographic, exposure and clinical data are available: (1) demographic information; (2) smoking details: (3) markers of underlying lung disease: (4) existing imaging (5) clinical information/pathological findings. For this ICTR pilot:
Cough will be captured in aerochamber (common, disposable handheld spacer device for asthma meter dose inhalers/pumps). The investigator team has found that it is an adequate cough (forced exhalation) capture device, pending further optimization. Under a planned amendment, the patient is instructed to cough every 30 seconds into the handheld plastic chamber, during an overall period of 10 minutes. All inside surfaces of the entire chamber is then rinsed with 2-4 ml of PBS, and the rinse/wash is snap frozen. The rinse is subsequently processed according to the analyte to be studied. For DNA, there is an Isopropanol/EtOH precipitation step, followed by resuspension in smaller volume, and extraction by Qiagen/Zymo DNA isolation kit. For protein, the crude extract in PBS is handled directly in the core by precipitation, drying, resuspension in buffer, and injection in the LC-MS platform for shotgun analyses.
The EV partitioning procedure is published. EV-CATCHER™ can be customized to target unique surface membrane proteins particular to the desired cell type and thus to direct capture of cell-specific EVs. The Loudig lab has compiled extensive data demonstrating, for example, that using antibodies targeting deep lung cell unique and specific proteins (e.g., Clara Cell Specific protein (CCSP), Alveolar type 2 cell Surfactant Protein-C (SFTPC)) can specifically purify EVs from Bronchoalveolar lavages (BAL) and exhaled breath condensates (EBC) and obtain similar miRNA expression profiles. Finally, by adding an enzymatically degradable uracylated double-stranded biotin-labeled DNA linker between immobilizing platform (polystyrene 96-well plate) and the activated antibody, the intact release of immunopurified EVs by incubation with uracil glycosylase (UNG) can be facilitated.
Approach: Aliquots from the 10 initial donors providing cough, mouthrinse, and BAL samples (5 current smokers, 5 never smokers) totaling 30 initial samples among all sample types for EV partitioning. Then, both whole-unpartitioned and EV-partitioned samples will be generated (totaling 60 samples) to be triaged to the two main assays, SMM for somatic mutation, and shotgun proteomics, below, both for feasibility demonstration, and pilot evaluation of surrogacy of cough for lung.
Aim 2: Cough will undergo DNA mutation analyses using SMM. Direct analysis of genome sequence integrity in normal cells. A key problem in studying genome sequence integrity in normal human tissues is the random nature of DNA mutations in the genome. While some mutations are clonally amplified, the vast majority are unique to each cell, and therefore rare and variant, which necessitates either single-cell whole genome amplification or in vitro clonal amplification assays. Both approaches have been associated with artifacts. Recently, the Maslov/Vijg lab developed reliable methods to quantitatively assess somatic mutations in single cells or in clonally amplified single cells. Using these methods it was demonstrated that base substitution mutations increase with smoking (and age) in proximal bronchial epithelial basal cells. A newer method for the quantitative analysis of somatic mutations, Single Molecule Mutation-seq (SMM-seq), is much more cost effective and can be applied to small amounts of bulk DNA. This latest SMM-seq method is significant because it allows, among other considerations, a practical means to accurately detect mutations in cytologically normal cells.
Approach: The 20 cough samples (10 unfractionated, 10 fractionated) will undergo DNA extraction, and library preparation and sequencing as described in the protocol. Somatic mutations among all the detected variants occurs by subtraction of germline polymorphisms found by analysis of regular sequencing library from DNA of the same individual. The number of somatic variants is normalized to the number of callable bases, i.e., bases with coverage more than 7X in SMM-seq libraries and with coverage more than 20X in regular libraries. Somatic mutation frequency will be expressed as a number of mutations per genome. The remaining 40 samples (20 from mouthwash and 20 from BAL) will be processed under other ongoing funding mechanisms, given budgetary constraints.
Aim 3: Cough, mouthwash, and BAL will undergo proteomic analysis using LC-MS in Einstein's Core facility. Prior proteomics attempts in cough do not exist to the investigator team's knowledge, perhaps due to technical limitations of low abundance material. The proteomics core (Sidoli, et al) will optimize a strategy to enhance sensitivity and speed for quantifying low abundance proteins/peptides. The sample preparation protocol will be modified to minimize sample loss and miniaturize nano-liquid chromatography coupled with state-of-the-art MS to quantify proteins/peptides in BAL, MW, and EBC specimens.
Approach: Sample preparation for proteomics: Cough specimen is dried to completion and then resuspended in 5 µL of 50 mM ammonium bicarbonate (pH = 8) for canonical proteomics sample preparation (20 ng of trypsin). The entire sample is then analyzed using a Dionex RSLC Ultimate 300 (Thermo Scientific) nano-liquid chromatographer coupled online with an Orbitrap Fusion Lumos (Thermo Scientific) mass spectrometer. For separation, the lab will utilize an in-house packed analytical column with minimal internal diameter (50 µm ID, 25 cm length) so that molecules with a \~100 nL/min flow-rate can be separated. The low flow-rate provides enhanced pre-concentration of the sample eluting from the column, leading to sub-attomole sensitivity.
Data analysis, including data transformation, is then performed using a pipeline in the Sidoli lab. Briefly, proteomics MS spectra are identified and quantified using Proteome Discoverer (v2.5, Thermo Scientific) with thresholds more stringent than currently recommended by the community for false discovery rate (\<1% FDR for spectrum matches, peptides and proteins). Quantitative values are then transformed and normalized as described by the Sidoli lab. Statistical regulation is assessed using parametric statistics (p\< 0.05). Chromatograms are manually inspected, given the relatively short list of candidates.
All cough samples (10 unfractionated, 10 fractionated x 3 specimen types=60 samples) will undergo proteomic analysis as described.
Cross-compartment comparisons: Determining cough surrogacy for lung can be performed in analogous fashion to that performed for EBC surrogacy for the lung. Within a given platform, the levels (and signature) of SMM mutation will be compared. In the recent past in the exhaled microRNA environment (not proposed here), this has been performed by Spearman correlations of microRNA-seq data clustering in principal components, PCA (not shown) and Spearman correlations (not shown). For the proteomics environment, this surrogacy of cough for lung can be shown for cough similarly by clustering heatmaps, PCA, and methods such as Spearman correlation.
Outcome: This initial pilot testing of cough as a new platform biospecimen is high risk, high reward pragmatic translational work. If this pilot project shows cough to be a valid surrogate for lung, on the two platforms examined, then that will provide strong preliminary evidence for supporting further federal funding. This potential for an airway based portal to the lung could be envisioned for a wide variety of acute and chronic clinical and public health purposes.
Proposal in Brief: For development of an epidemiological and clinically-applicable platform for large molecules captured uniquely from deep lung, the investigator team will pursue a new approach that includes cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL/bronchial brushings, and to the potential contaminating mouthrinse, all from the same individuals. The study team initially proposes to examine these crude cough specimens, and then EV partitioned airway samples, for somatic mutations by SMM bulk sequencing for somatic mutations, state-of-art techniques developed in the Vijg/Maslov labs and for proteins known to be specific for lung, as opposed to oral cavity/saliva, in the Sidoli/proteomics core.
Specific Aims:
1. Cough will be captured by aerochamber or equivalent/optimized device in 5 healthy volunteers, and in 5 current smokers, in parallel with mouthrinse and with BAL. Lung-specific EVs from these same samples via deep lung capture (Loudig lab) will be performed in parallel.
2. Cough will undergo DNA mutation analyses using single molecule mutation sequencing (SMM-seq).
3. Cough, mouthwash and BAL will undergo proteomic analysis using LC-MS in our Core facility.
Aims 1 and 2 will be studied in a cross-sectional manner, enrolling a convenience sample of PLWHA smokers attending the Montefiore Medical Center (MMC) Infectious Diseases (ID) Clinic. During Aim 1, group EBC DNA methylation and microRNA and metabolomics patterns will be determined by high resolution tagged bisulfite genomic sequencing of three tumor suppressor genes (DAPK, RASSF1A, PAX5B), according to smoking status (current, former, never), and lifelong dose (pack-years) in a sample of HIV-infected smokers. Aim 2 will pilot the comparison of EBC DNA methylation and microRNA and metabolomics patterns from HIV infected individuals to that from uninfected individuals, collected in other projects funded by other mechanisms. Aim 3 will employ a prospective design, collecting two specimens over time from a subset of the overall study sample to examine the stability of EBC DNA and microRNA and metabolomics patterns methylation patterns over time in HIV-infected smokers.
Approach:
Human Lung Studies protocol practices, in general: Ongoing subject enrollment is part of a longstanding IRB-approved Einstein-Montefiore clinical case-control protocol (2007-407). Individuals from pulmonary practices eligible to enroll are: Age \> 21 years old, any smoking status, myriad comorbid status except contraindications to BAL, planned for clinically-indicated lung collection procedure (bronchoscopy) as part of routine care. This amounts to \>100-150 bronchoscopy and related former smoker donors recruits per year. Over 150-200 such pre-existing bronchoscopic sample sets, and attendant non-invasive EBC, along with MW, buccal brush, others\] are banked and potentially available for the current study. All data/specimens are collected pre-diagnosis and pre-procedure; each subject provides EBC (and other non-invasives such as Cough) samples pre- bronchoscopy. As such, this active protocol minimizes (i) recall bias; and (ii) contamination of non-invasive specimens from the disruptions and spillage of the lung tissue inherent to these lung procedures. Each subject will be followed for 3 months in the medical record to gather updated diagnostics/testing, and minimize case-control misclassification. Extensive demographic, exposure and clinical data are available: (1) demographic information; (2) smoking details: (3) markers of underlying lung disease: (4) existing imaging (5) clinical information/pathological findings. For this ICTR pilot:
Cough will be captured in aerochamber (common, disposable handheld spacer device for asthma meter dose inhalers/pumps). The investigator team has found that it is an adequate cough (forced exhalation) capture device, pending further optimization. Under a planned amendment, the patient is instructed to cough every 30 seconds into the handheld plastic chamber, during an overall period of 10 minutes. All inside surfaces of the entire chamber is then rinsed with 2-4 ml of PBS, and the rinse/wash is snap frozen. The rinse is subsequently processed according to the analyte to be studied. For DNA, there is an Isopropanol/EtOH precipitation step, followed by resuspension in smaller volume, and extraction by Qiagen/Zymo DNA isolation kit. For protein, the crude extract in PBS is handled directly in the core by precipitation, drying, resuspension in buffer, and injection in the LC-MS platform for shotgun analyses.
The EV partitioning procedure is published. EV-CATCHER™ can be customized to target unique surface membrane proteins particular to the desired cell type and thus to direct capture of cell-specific EVs. The Loudig lab has compiled extensive data demonstrating, for example, that using antibodies targeting deep lung cell unique and specific proteins (e.g., Clara Cell Specific protein (CCSP), Alveolar type 2 cell Surfactant Protein-C (SFTPC)) can specifically purify EVs from Bronchoalveolar lavages (BAL) and exhaled breath condensates (EBC) and obtain similar miRNA expression profiles. Finally, by adding an enzymatically degradable uracylated double-stranded biotin-labeled DNA linker between immobilizing platform (polystyrene 96-well plate) and the activated antibody, the intact release of immunopurified EVs by incubation with uracil glycosylase (UNG) can be facilitated.
Approach: Aliquots from the 10 initial donors providing cough, mouthrinse, and BAL samples (5 current smokers, 5 never smokers) totaling 30 initial samples among all sample types for EV partitioning. Then, both whole-unpartitioned and EV-partitioned samples will be generated (totaling 60 samples) to be triaged to the two main assays, SMM for somatic mutation, and shotgun proteomics, below, both for feasibility demonstration, and pilot evaluation of surrogacy of cough for lung.
Aim 2: Cough will undergo DNA mutation analyses using SMM. Direct analysis of genome sequence integrity in normal cells. A key problem in studying genome sequence integrity in normal human tissues is the random nature of DNA mutations in the genome. While some mutations are clonally amplified, the vast majority are unique to each cell, and therefore rare and variant, which necessitates either single-cell whole genome amplification or in vitro clonal amplification assays. Both approaches have been associated with artifacts. Recently, the Maslov/Vijg lab developed reliable methods to quantitatively assess somatic mutations in single cells or in clonally amplified single cells. Using these methods it was demonstrated that base substitution mutations increase with smoking (and age) in proximal bronchial epithelial basal cells. A newer method for the quantitative analysis of somatic mutations, Single Molecule Mutation-seq (SMM-seq), is much more cost effective and can be applied to small amounts of bulk DNA. This latest SMM-seq method is significant because it allows, among other considerations, a practical means to accurately detect mutations in cytologically normal cells.
Approach: The 20 cough samples (10 unfractionated, 10 fractionated) will undergo DNA extraction, and library preparation and sequencing as described in the protocol. Somatic mutations among all the detected variants occurs by subtraction of germline polymorphisms found by analysis of regular sequencing library from DNA of the same individual. The number of somatic variants is normalized to the number of callable bases, i.e., bases with coverage more than 7X in SMM-seq libraries and with coverage more than 20X in regular libraries. Somatic mutation frequency will be expressed as a number of mutations per genome. The remaining 40 samples (20 from mouthwash and 20 from BAL) will be processed under other ongoing funding mechanisms, given budgetary constraints.
Aim 3: Cough, mouthwash, and BAL will undergo proteomic analysis using LC-MS in Einstein's Core facility. Prior proteomics attempts in cough do not exist to the investigator team's knowledge, perhaps due to technical limitations of low abundance material. The proteomics core (Sidoli, et al) will optimize a strategy to enhance sensitivity and speed for quantifying low abundance proteins/peptides. The sample preparation protocol will be modified to minimize sample loss and miniaturize nano-liquid chromatography coupled with state-of-the-art MS to quantify proteins/peptides in BAL, MW, and EBC specimens.
Approach: Sample preparation for proteomics: Cough specimen is dried to completion and then resuspended in 5 µL of 50 mM ammonium bicarbonate (pH = 8) for canonical proteomics sample preparation (20 ng of trypsin). The entire sample is then analyzed using a Dionex RSLC Ultimate 300 (Thermo Scientific) nano-liquid chromatographer coupled online with an Orbitrap Fusion Lumos (Thermo Scientific) mass spectrometer. For separation, the lab will utilize an in-house packed analytical column with minimal internal diameter (50 µm ID, 25 cm length) so that molecules with a \~100 nL/min flow-rate can be separated. The low flow-rate provides enhanced pre-concentration of the sample eluting from the column, leading to sub-attomole sensitivity.
Data analysis, including data transformation, is then performed using a pipeline in the Sidoli lab. Briefly, proteomics MS spectra are identified and quantified using Proteome Discoverer (v2.5, Thermo Scientific) with thresholds more stringent than currently recommended by the community for false discovery rate (\<1% FDR for spectrum matches, peptides and proteins). Quantitative values are then transformed and normalized as described by the Sidoli lab. Statistical regulation is assessed using parametric statistics (p\< 0.05). Chromatograms are manually inspected, given the relatively short list of candidates.
All cough samples (10 unfractionated, 10 fractionated x 3 specimen types=60 samples) will undergo proteomic analysis as described.
Cross-compartment comparisons: Determining cough surrogacy for lung can be performed in analogous fashion to that performed for EBC surrogacy for the lung. Within a given platform, the levels (and signature) of SMM mutation will be compared. In the recent past in the exhaled microRNA environment (not proposed here), this has been performed by Spearman correlations of microRNA-seq data clustering in principal components, PCA (not shown) and Spearman correlations (not shown). For the proteomics environment, this surrogacy of cough for lung can be shown for cough similarly by clustering heatmaps, PCA, and methods such as Spearman correlation.
Outcome: This initial pilot testing of cough as a new platform biospecimen is high risk, high reward pragmatic translational work. If this pilot project shows cough to be a valid surrogate for lung, on the two platforms examined, then that will provide strong preliminary evidence for supporting further federal funding. This potential for an airway based portal to the lung could be envisioned for a wide variety of acute and chronic clinical and public health purposes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Lung Diseases
Lung Cancer
Lung Diseases, Obstructive
Lung Diseases, Interstitial
Lung Inflammation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bronchoscopy subjects, current or former smokers
Bronchoscopy subjects \>=21 yo, current or former smokers
Observational only, all subjects; measure DNA mutation and proteomic survey.
Intervention Type
OTHER
Observational only, all subjects; measure DNA mutation and proteomic survey.
Bronchoscopy subjects, never smokers
Bronchoscopy subjects \>=21 yo, never smokers
Observational only, all subjects; measure DNA mutation and proteomic survey.
Intervention Type
OTHER
Observational only, all subjects; measure DNA mutation and proteomic survey.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational only, all subjects; measure DNA mutation and proteomic survey.
Observational only, all subjects; measure DNA mutation and proteomic survey.
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Observational study to develop a cough diagnostic
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: minimum age of 21 years
* Gender: Male and Female adults
* Ethnicity: All ethnic groups and races
* Subjects undergoing bronchoscopy for diagnostic purposes or therapy
* Subjects without a known diagnosis of lung cancer who are not scheduled for lung tissue collection procedures
* Subjects with a known or suspected diagnosis of asthma or COPD and are scheduled for a visit at Montefiore Asthma or COPD Center and individual practices, and/or in-hospital with exacerbation
* Gender: Male and Female adults
* Ethnicity: All ethnic groups and races
* Subjects undergoing bronchoscopy for diagnostic purposes or therapy
* Subjects without a known diagnosis of lung cancer who are not scheduled for lung tissue collection procedures
* Subjects with a known or suspected diagnosis of asthma or COPD and are scheduled for a visit at Montefiore Asthma or COPD Center and individual practices, and/or in-hospital with exacerbation
Exclusion Criteria
* Bleeding diathesis or known coagulopathy precluding clinically indicated biopsy (e.g., INR\>1.3, PTTr\>1.3), thrombocytopenia \<50,000, uremia with serum creatinine \>3.0
* Unstable angina
* Recent myocardial infarction (within 3 months),
* Uncontrolled congestive heart failure or severe pulmonary hypertension (mean PAP\>75 mmHg)
* Unstable angina
* Recent myocardial infarction (within 3 months),
* Uncontrolled congestive heart failure or severe pulmonary hypertension (mean PAP\>75 mmHg)
Minimum Eligible Age
21 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Advancing Translational Sciences (NCATS)
NIH
Sponsor Role
collaborator
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Sponsor Role
collaborator
National Institute of Environmental Health Sciences (NIEHS)
NIH
Sponsor Role
collaborator
Evaluate Diagnostics
UNKNOWN
Sponsor Role
collaborator
James J. Peters Veterans Affairs Medical Center
FED
Sponsor Role
collaborator
Touro University
OTHER
Sponsor Role
collaborator
Hackensack Meridian Health
OTHER
Sponsor Role
collaborator
The Scripps Research Institute
OTHER
Sponsor Role
collaborator
Weill Medical College of Cornell University
OTHER
Sponsor Role
collaborator
Cold Spring Harbor Laboratory
OTHER
Sponsor Role
collaborator
Albert Einstein College of Medicine
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simon D Spivack, MD
Role: PRINCIPAL_INVESTIGATOR
Albert Einstein College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Albert Einstein College of Medicine
The Bronx, New York, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Mitchell MI, Ben-Dov IZ, Ye K, Liu C, Shi M, Sadoughi A, Shah C, Siddiqui T, Okorozo A, Gutierrez M, Unawane R, Biamonte L, Parikh K, Spivack S, Loudig O. Exhaled breath condensate contains extracellular vesicles (EVs) that carry miRNA cargos of lung tissue origin that can be selectively purified and analyzed. J Extracell Vesicles. 2024 Apr;13(4):e12440. doi: 10.1002/jev2.12440.
Reference Type
BACKGROUND
Shi M, Han W, Loudig O, Shah CD, Dobkin JB, Keller S, Sadoughi A, Zhu C, Siegel RE, Fernandez MK, DeLaRosa L, Patel D, Desai A, Siddiqui T, Gombar S, Suh Y, Wang T, Hosgood HD, Pradhan K, Ye K, Spivack SD. Initial development and testing of an exhaled microRNA detection strategy for lung cancer case-control discrimination. Sci Rep. 2023 Apr 24;13(1):6620. doi: 10.1038/s41598-023-33698-8.
Reference Type
BACKGROUND
Huang Z, Sun S, Lee M, Maslov AY, Shi M, Waldman S, Marsh A, Siddiqui T, Dong X, Peter Y, Sadoughi A, Shah C, Ye K, Spivack SD, Vijg J. Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smoking. Nat Genet. 2022 Apr;54(4):492-498. doi: 10.1038/s41588-022-01035-w. Epub 2022 Apr 11.
Reference Type
BACKGROUND
Zefi O, Waldman S, Marsh A, Shi MK, Sonbolian Y, Khulan B, Siddiqui T, Desai A, Patel D, Okorozo A, Khader S, Dobkin J, Sadoughi A, Shah C, Spivack S, Peter Y. Distinctive field effects of smoking and lung cancer case-control status on bronchial basal cell growth and signaling. Respir Res. 2024 Aug 19;25(1):317. doi: 10.1186/s12931-024-02924-w.
Reference Type
RESULT
Khulan B, Ye K, Shi MK, Waldman S, Marsh A, Siddiqui T, Okorozo A, Desai A, Patel D, Dobkin J, Sadoughi A, Shah C, Gera S, Peter Y, Liao W, Vijg J, Spivack SD. Normal bronchial field basal cells show persistent methylome-wide impact of tobacco smoking, including in known cancer genes. Epigenetics. 2025 Dec;20(1):2466382. doi: 10.1080/15592294.2025.2466382. Epub 2025 Feb 20.
Reference Type
RESULT
S.D. Spivack, M.W. Azam, A. Okorozo, K. Batbayar, A.Y. Maslov, M. Lee, J. Vijg, and O. Loudig. Development of Cough Access to the Deep Lung for Somatic Mutagenesis Assessment [abstract]. Am J Respir Crit Care Med 2025;211:A4800. https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A4800
Reference Type
RESULT
S.D. Spivack, O. Zefi, S. Waldman, M. Shi, T. Siddiqui, A. Desai, D. Patel, A. Okorozo, J.B. Dobkin, A. Sadoughi, and C. Shah. Altered Bronchialbasal Cell Morphology and Growth Phenotypes in Field Carcinogenesis Correspond With Altered Notch Signaling Patterns [abstract]. Am J Respir Crit Care Med 2025;211:A7917. https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A791
Reference Type
RESULT
S.D. Spivack, K. Batbayar, A. Maslov, M. Lee, M.W. Azam, and J. Vijg. Genome-wide Tobacco Smoke Mutagenesis Modelled in Long Term HBEC Bronchial Basal Epithelial Cells In Vitro [abstract]. Am J Respir Crit Care Med 2025;211:A4801. https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A4801
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-407
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Biomarkers for Early Detection of Lung Cancer in Patients With Lung Cancer, Participants at High-Risk for Developing Lung Cancer, or Healthy Volunteers
NCT00899262
UNKNOWN
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
NCT01414595
COMPLETED
Liquid Biopsy in Lung Cancer
NCT03479099
COMPLETED
'Lung Health Check' Biomarker Study
NCT04957433
UNKNOWN
Circulating Tumor Cells in Lung Cancer Screening
NCT02500693
COMPLETED
NA
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
NCT07331701
NOT_YET_RECRUITING
Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment
NCT06086587
NOT_YET_RECRUITING
Role of Bronchoscopy in Early Lung Cancer Screening of High Risk Population
NCT02277366
TERMINATED
Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer
NCT00002667
COMPLETED
NA
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
NCT00019201
COMPLETED
NA
The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
NCT02380196
COMPLETED
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
NCT02146170
RECRUITING
Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer
NCT01958931
COMPLETED
Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer
NCT00003006
COMPLETED
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
NCT01830426
COMPLETED
Circulating Tumor DNA in Patients at High Risk for Lung Cancer
NCT02715102
TERMINATED
Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells)
NCT04957602
TERMINATED
Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers
NCT06816121
NOT_YET_RECRUITING
Metabolic and Microbial Profiling of Lung Cancer
NCT03998189
TERMINATED
NA
Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker
NCT01700257
COMPLETED
NA
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
NCT03499678
TERMINATED
EB-OCT Biopsy Guidance of Lung Cancer
NCT06556680
NOT_YET_RECRUITING
NA
Real-Time Optical Biopsy in Improving Lung Cancer Diagnosis in Patients Undergoing Lung Biopsy
NCT03376971
COMPLETED
NA
A Multi-Center Trial of the ProLung Test™
NCT01566682
COMPLETED